Page 1513 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 84 Malignant Lymphomas in Childhood 1342.e3

children and adolescents with B-cell neoplasms: a report of the BFM consecutive studies of the French Society of Pediatric Oncology. Blood
Group Study NHL-BFM95. Blood 105:948, 2005. 92:3591, 1998.
80. Pfreundschuh M, Trumper L, Osterborg A, et al: CHOP-like che- 100. Brugières L, Quartier P, Le Deley MC, et al: Relapses of childhood
motherapy plus rituximab versus CHOP-like chemotherapy alone in anaplastic large-cell lymphoma: treatment results in a series of 41
young patients with good-prognosis diffuse large-B-cell lymphoma: children—a report from the French Society of Pediatric Oncology.
a randomised controlled trial by the MabThera International Trial Ann Oncol 11:53, 2000.
(MInT) Group. Lancet Oncol 7:379, 2006. 101. Le Deley MC, Rosolen A, Williams DM, et al: Vinblastine in children
81. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP and adolescents with high-risk anaplastic large-cell lymphoma: results of
versus CHOP alone or with maintenance rituximab in older patients the randomized ALCL99-vinblastine trial. J Clin Oncol 28:3987, 2010.
with diffuse large B-cell lymphoma. J Clin Oncol 24:3121, 2006. 102. Wrobel G, Mauguen A, Rosolen A, et al: Safety assessment of intensive
82. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus ritux- induction therapy in childhood anaplastic large cell lymphoma: report
imab compared with CHOP alone in elderly patients with diffuse of the ALCL99 randomised trial. Pediatr Blood Cancer 56:1071, 2011.
large-B-cell lymphoma. N Engl J Med 346:235, 2002. 103. Gambacorti-Passerini C, Messa C, Pogliani EM: Crizotinib in anaplas-
+
83. Kadin ME: Ki-1/CD30 (anaplastic) large-cell lymphoma: maturation tic large-cell lymphoma. N Engl J Med 364:775, 2011.
of a clinicopathologic entity with prospects of effective therapy. J Clin 104. Pro B, Advani R, Brice P, et al: Brentuximab vedotin (SGN-35) in
Oncol 12:884, 1994. patients with relapsed or refractory systemic anaplastic large-cell lym-
84. Nadali G, Vinante F, Stein H, et al: Serum levels of the soluble form phoma: results of a phase II study. J Clin Oncol 30:2190, 2012.
+
of CD30 molecule as a tumor marker in CD30 anaplastic large-cell 105. Gross TG, Hale GA, He W, et al: Hematopoietic stem cell transplanta-
lymphoma. J Clin Oncol 13:1355, 1995. tion for refractory or recurrent non-Hodgkin lymphoma in children
85. Mason DY, Bastard C, Rimokh R, et al: CD30-positive large cell and adolescents. Biol Blood Marrow Transplant 16:223, 2010.
lymphomas (‘Ki-1 lymphoma’) are associated with a chromosomal 106. Griffin TC, Weitzman S, Weinstein H, et al: A study of rituximab
translocation involving 5q35. Br J Haematol 74:161, 1990. and ifosfamide, carboplatin, and etoposide chemotherapy in children
+
+
+
86. Morris SW, Xue L, Ma Z, et al: Alk CD30 lymphomas: a distinct with recurrent/refractory B-cell (CD20 ) non-Hodgkin lymphoma
molecular genetic subtype of non-Hodgkin’s lymphoma. Br J Haematol and mature B-cell acute lymphoblastic leukemia: a report from the
113:275, 2001. Children’s Oncology Group. Pediatr Blood Cancer 52:177, 2009.
+
87. Rodriguez J, Pugh W, Romaguera J, et al: Anaplastic Ki-1 large-cell 107. Attarbaschi A, Dworzak M, Steiner M, et al: Outcome of children
lymphoma. Cancer Invest 11:554, 1993. with primary resistant or relapsed non-Hodgkin lymphoma and mature
+
88. Stein H, Foss HD, Durkop H, et al: CD30 anaplastic large cell lym- B-cell leukemia after intensive first-line treatment: a population-based
phoma: a review of its histopathologic, genetic, and clinical features. analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer
Blood 96:3681, 2000. 44:70, 2005.
89. Murphy SB: Pediatric lymphomas: recent advances and commentary on 108. Mitsui T, Mori T, Fujita N, et al: Retrospective analysis of relapsed
Ki-1-positive anaplastic large-cell lymphomas of childhood. Ann Oncol or primary refractory childhood lymphoblastic lymphoma in Japan.
5(Suppl 1):31, 1994. Pediatr Blood Cancer 52:591, 2009.
90. Link MP, Shuster JJ, Donaldson SS, et al: Treatment of children and 109. Burkhardt B, Reiter A, Landmann E, et al: Poor outcome for children
young adults with early-stage non-Hodgkin’s lymphoma. N Engl J Med and adolescents with progressive disease or relapse of lymphoblastic
337:1259, 1997. lymphoma: a report from the Berlin-Frankfurt-Münster Group. J Clin
91. Lowe EJ, Sposto R, Perkins SL, et al: Intensive chemotherapy for Oncol 27:3363, 2009.
systemic anaplastic large cell lymphoma in children and adolescents: 110. Berg SL, Blaney SM, Devidas M, et al: Phase II study of nelarabine
final results of Children’s Cancer Group Study 5941. Pediatr Blood (compound 506U78) in children and young adults with refractory
Cancer 52:335, 2009. T-cell malignancies: a report from the Children’s Oncology Group. J
92. Seidemann K, Tiemann M, Schrappe M, et al: Short-pulse B-non- Clin Oncol 23:3376, 2005.
Hodgkin lymphoma-type chemotherapy is efficacious treatment 111. Mori T, Takimoto T, Katano N, et al: Recurrent childhood anaplastic
for pediatric anaplastic large cell lymphoma: a report of the Berlin- large cell lymphoma: a retrospective analysis of registered cases in Japan.
Frankfurt-Münster Group Trial NHL-BFM 90. Blood 97:3699, 2001. Br J Haematol 132:594, 2006.
93. Le Deley MC, Reiter A, Williams D, et al: Prognostic factors in 112. Brugières L, Pacquement H, Le Deley MC, et al: Single-drug vinblas-
childhood anaplastic large cell lymphoma: results of a large European tine as salvage treatment for refractory or relapsed anaplastic large-cell
intergroup study. Blood 111:1560, 2008. lymphoma: a report from the French Society of Pediatric Oncology. J
94. Alexander S, Kraveka JM, Weitzman S, et al: Advanced stage anaplastic Clin Oncol 27:5056, 2009.
large cell lymphoma in children and adolescents: results of ANHL0131, 113. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-
a randomized phase III trial of APO versus a modified regimen with 35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812,
vinblastine: a report from the Children’s Oncology Group. Pediatr Blood 2010.
Cancer 61:2236, 2014. 114. Woessmann W, Peters C, Lenhard M, et al: Allogeneic haematopoietic
95. Woo DK, Jones CR, Vanoli-Storz MN, et al: Prognostic factors in stem cell transplantation in relapsed or refractory anaplastic large cell
primary cutaneous anaplastic large cell lymphoma: characterization of lymphoma of children and adolescents—a Berlin-Frankfurt-Münster
clinical subset with worse outcome. Arch Dermatol 145:667, 2009. Group report. Br J Haematol 133:176, 2006.
96. Ait-Tahar K, Damm-Welk C, Burkhardt B, et al: Correlation of the 115. Bhatia S, Ramsay NK, Steinbuch M, et al: Malignant neoplasms fol-
autoantibody response to the ALK oncoantigen in pediatric anaplastic lowing bone marrow transplantation. Blood 87:3633, 1996.
lymphoma kinase-positive anaplastic large cell lymphoma with tumor 116. Oertel SH, Riess H: Immunosurveillance, immunodeficiency and
dissemination and relapse risk. Blood 115:3314, 2010. lymphoproliferations. Recent Results Cancer Res 159:1, 2002.
97. Lamant L, McCarthy K, d’Amore E, et al: Prognostic impact of 117. Kuehnle I, Huls MH, Liu Z, et al: CD20 monoclonal antibody (ritux-
morphologic and phenotypic features of childhood ALK-positive imab) for therapy of Epstein-Barr virus lymphoma after hemopoietic
anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin stem-cell transplantation. Blood 95:1502, 2000.
Oncol 29:4669, 2011. 118. O’Reilly RJ, Lacerda JF, Lucas KG, et al: Adoptive cell therapy with
98. Laver JH, Kraveka JM, Hutchison RE, et al: Advanced-stage large-cell donor lymphocytes for EBV-associated lymphomas developing after
lymphoma in children and adolescents: results of a randomized trial allogeneic marrow transplants. Important Adv Oncol 149:1996.
incorporating intermediate-dose methotrexate and high-dose cytarabine 119. Heslop HE, Slobod KS, Pule MA, et al: Long-term outcome of EBV-
in the maintenance phase of the APO regimen: a Pediatric Oncology specific T-cell infusions to prevent or treat EBV-related lymphoprolif-
Group phase III trial. J Clin Oncol 23:541, 2005. erative disease in transplant recipients. Blood 115:925, 2010.
+
99. Brugières L, Deley MC, Pacquement H, et al: CD30 anaplastic large- 120. Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al: Adoptive immuno-
+
cell lymphoma in children: analysis of 82 patients enrolled in two therapy with unselected or EBV-specific T cells for biopsy-proven EBV